Bortezomib‐thalidomide‐dexamethasone versus bortezomib‐cyclophosphamide‐dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|168|4|605-606

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.168, Iss.4, 2015-02, pp. : 605-606

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bortezomib, thalidomide and dexamethasone versus bortezomib, cyclophosphamide and dexamethasone as induction therapy prior to ASCT in multiple myeloma – response to Moreau et al

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 4, 2015-02 ,pp. : 604-605

John Wiley & Sons Inc

Access to resources Recommend Favorite

Thalidomide, Cyclophosphamide and Dexamethasone Induction Therapy: Feasibility for Myeloma Patients Destined for Autologous Stem Cell Transplantation

By  

Acta Haematologica, Vol. 132, Iss. 2, 2014-04 ,pp. : 226-232

Karger

Access to resources Recommend Favorite

Bortezomib with Thalidomide plus Dexamethasone Compared with Thalidomide plus Doxorubicin and Dexamethasone as Induction Therapy in Previously Untreated Multiple Myeloma Patients

By  

Acta Haematologica, Vol. 129, Iss. 1, 2012-10 ,pp. : 35-39

Karger

Access to resources Recommend Favorite

A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 1, 2015-04 ,pp. : 36-43

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 3, 2015-11 ,pp. : 344-354

John Wiley & Sons Inc

Access to resources Recommend Favorite